Navigation Links
Alfacell Provides ONCONASE(R) NDA Submission Update
Date:1/27/2009

SOMERSET, N.J., Jan. 27 /PRNewswire-FirstCall/ -- Alfacell Corporation (OTC Bulletin Board: ACEL) today reported that it has conducted a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) to discuss the company's planned submission of the final components of the ONCONASE rolling New Drug Application (NDA) for the treatment of unresectable malignant mesothelioma (UMM) patients. At the pre-NDA meeting, the FDA provided guidance to the company recommending that an additional clinical trial be conducted in UMM patients that have failed one prior chemotherapy regimen, prior to submitting a NDA.

As the company has previously reported, the results of the preliminary statistical analysis of the data from the confirmatory Phase IIIb clinical trial for ONCONASE in patients suffering from UMM did not meet statistical significance for the primary endpoint of survival in UMM. However, a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen, a pre-defined primary data set for this sub-group of patients in the trial, which represents a currently unmet medical need.

The company's current financial situation does not allow it to pursue additional clinical trials until other sources of capital are secured. The company will effect a reduction in force on January 30, 2009 and otherwise reduce its operations to the minimum sustainable level required to pursue strategic alternatives and additional capital. Based upon these actions the company expects that its current cash reserves will enable it to maintain its reduced operations through December 2009. The company intends to continue to explore strategic alternatives and additional capital. Additionally, the company's board of directors has agreed to forgo cash compensation effective as of January 1, 2009.

About ONCONASE(R)

ONCONASE is a first-in-class therapeuti
'/>"/>

SOURCE Alfacell Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alfacells ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
2. Alfacell Receives Going Concern Audit Opinion
3. Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
4. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
5. Alfacell Hires Advisors to Advance Strategic Alternatives
6. Alfacell Receives NASDAQ Delisting Letter
7. Alfacell Receives NASDAQ Non-Compliance Notification
8. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
9. Alfacell Announces Retirement of Chief Executive Officer
10. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
11. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 According to ... by Service Type (Consulting, Integration, Deployment & Support), ... Deployment Model (Public, Private, Others (Hybrid & Community)) ... defines and segments the Cloud Professional Services Market ... forecasting of revenues. It also identifies the drivers ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by product ... Table-top Counters) by End-user (Inpatient Pharmacy Automation, Outpatient ... 2019” analyzes and studies the major market drivers, ... and the Rest of the World (RoW). , ... through 300 pages and in-depth TOC on "Pharmacy ...
(Date:10/20/2014)... Calif. , Oct. 20, 2014 ... that the Company has signed a Notice of ... Regenerative Medicine (CIRM), effective October 1, 2014.  The ... Development payments and the release of additional grant ... CIRM grant award for clinical development of Asterias, ...
Breaking Biology Technology:Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... CITY, Oct. 7 Great Basin Scientific, Inc., ... diagnostic solutions, today announced it had closed a ... in the,funding for this round., The new ... the spring of,2009 as it completes the design ...
... List for Fourth Consecutive Year, INDIANAPOLIS, ... one of the magazine,s Top 500 innovative ... a handful of companies in the biotech,and ... No. 86, in the 2008 report,outperformed others ...
... Vical Incorporated (Nasdaq:,VICL) and AnGes MG, Inc., ... mutual interest to license the development and marketing,rights ... to AnGes. AnGes,plans to conduct due diligence on ... to negotiate terms and conditions potentially leading,to a ...
Cached Biology Technology:Great Basin Scientific, Inc. Closes $3.9 Million in Equity Funding 2InformationWeek Puts Roche Diagnostics on Top 500 Innovative Tech Users List 2Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program 2
(Date:10/22/2014)... Oct. 21, 2014 Aware, Inc. (NASDAQ: ... today reported financial results for its third quarter ended September ... 2014 was $6.0 million, an increase of 40% compared to ... in the third quarter of 2014 was $4.1 million compared ... operating income in the current three month period was primarily ...
(Date:10/18/2014)... and stress-related psychiatric disorders are associated with ... molecular mechanisms underlying this relation are unknown. ... development of targeted preventive strategies and new ... This work is presented at the European ... an international group of researchers from Germany ...
(Date:10/18/2014)... suspected genetic conditions, a certain type of exome sequencing ... than traditional molecular diagnostic methods, according to a study ... released to coincide with the American Society of Human ... protein­coding region of the genome (the complete set of ... organism), has been rapidly applied in research settings and ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Researchers find why depression and aging linked to increased disease risk 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3
... to noise of a diverse range of crustaceans, an international ... families of crustaceans previously assumed to be deaf could detect, ... the Great Barrier Reef, the team collected nearly 700,000 crustaceans, ... each of 34 nights, one light trap was attached to ...
... MD FASEB MARC (Minority Access to Research Careers) ... American College of Sports Medicine (ACSM) Texas Chapter Annual ... awards are meant to promote the entry of underrepresented ... the basic science community and to encourage the participation ...
... ( www.ucr.edu ) -- Ever wonder how much fuel ... window, not using air conditioning or coasting toward stops? ... of Engineering Center for Environmental Research and Technology (CE-CERT) ... is called eco-driving, which refers to providing drivers with ...
Cached Biology News:Rowdy residents warn crustaceans away from perilous reefs 2Research helps drivers cut fuel use 2Research helps drivers cut fuel use 3
Human/Rat Neurogenin-2 MAb (Clone 7G4) Protein Family: Neural Crest Cell Markers, Transcription Factors...
Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Mouse TREM-2 Affinity Purified Polyclonal Ab...
Biology Products: